Search results
-
ESMO 2024 – changing FDA stance could haunt Astra’s Niagara win
ESMO 2024 – changing FDA stance could haunt Astra’s …
- 09/16/2024 - 11:00 -
ESMO 2024 preview – Summit could take on Merck in breast cancer
ESMO 2024 preview – Summit could take on Merck in breast …
- 09/13/2024 - 21:05 -
ESMO 2024 preview – Astellas’s KRAS degrader disappoints
ESMO 2024 preview – Astellas’s KRAS degrader disappoints … degrader KRAS G12D inhibitor When presented ESMO 2024 ESMO 2023 Study Ph1 global study …
- 09/12/2024 - 15:49 -
ESMO 2024 – how Merck overreached in endometrial
ESMO 2024 – how Merck overreached in endometrial …
- 09/14/2024 - 07:37 -
ESMO 2024 – Incyte tries again in anal cancer
ESMO 2024 – Incyte tries again in anal cancer …
- 09/15/2024 - 08:35 -
Why Astra won’t find bladder cancer domination easy
… Toplined positive for EFS & OS Jun 2024; full data due at ESMO 2024 presidential session Nile 1L …
- 09/07/2024 - 17:40 -
ESMO 2024 preview – TIGIT gets its late-breaker
ESMO 2024 preview – TIGIT gets its late-breaker … the discontinuation of LOXO-783 . Selected ESMO 2024 late-breakers* Project Company …
- 09/09/2024 - 14:48 -
ESMO 2024 preview – presidential focus
ESMO 2024 preview – presidential focus … settings’ respective effects. Selected ESMO 2024 presidential presentations Project …
- 08/27/2024 - 16:15 -
Opdualag sets its sights on lung
… NSCLC Ph2 chemo combo, vs Opdivo + chemo, data at ESMO 2024 Relativity-069 2nd-line Hodgkin’s …
- 09/14/2024 - 08:05 -
Is this the end for MacroGenics’ vobra-duo?
… Ph2 Tamarack trial discontinued Jul 2024; more data due at ESMO 2024 Lorigerlimab Anti-PD-1 x CTLA-4 …
- 08/05/2024 - 12:30
